Results 231 to 240 of about 368,214 (310)

Dual Protease Inhibitor Therapy in HIV-Infected Patients: Pharmacologic Rationale and Clinical Benefits

Annual Review of Pharmacology and Toxicology, 2000
HIV protease inhibitors, as components of combination antiretroviral drug regimens, have substantially reduced the morbidity and mortality associated with HIV infection. They selectively block the action of the virus-encoded protease and stop the virus from replicating.
C. Flexner
openaire   +3 more sources

Clinical pharmacologic considerations for HIV-1 protease inhibitors

Current Infectious Disease Reports, 2001
Many data associate low protease inhibitor plasma concentrations with suboptimal virologic responses, whereas relatively few data associate high plasma concentrations with increased likelihood of toxicity. Knowledge of relationships between concentrations and virologic response is important because significant variability in plasma concentrations ...
Peter L., Anderson, Courtney V., Fletcher   +1 more
openaire   +2 more sources

Clinical pharmacology of HIV protease inhibitors in pregnancy

Current Opinion in HIV and AIDS, 2008
The use of highly active antiretroviral therapy during pregnancy has reduced the prevalence HIV of mother-to-child transmission (MTCT) dramatically. At present, the recommended first-line treatment for prevention of MTCT in developed countries is protease inhibitor-based highly active antiretroviral therapy.
Lugt, J. van der, Colbers, A., Burger, D.M.   +2 more
openaire   +3 more sources

Updated clinical pharmacologic considerations for HIV-1 protease inhibitors

Current HIV/AIDS Reports, 2004
Many data associate low protease inhibitor plasma concentrations with suboptimal virologic responses, whereas fewer data associate high plasma concentrations with toxicity. Knowledge of relationships between concentrations and virologic response is important because significant variability in concentrations exists among patients.
Peter L, Anderson, Courtney V, Fletcher
openaire   +2 more sources

Pharmacological enhancement of protease inhibitors with ritonavir: an update

Expert Review of Clinical Pharmacology, 2008
Advances in HIV treatment since the approval of the first antiretroviral (ARV) medication have occurred at a rapid pace. However, resistance to these medications can occur quickly owing to inadequate plasma concentrations resulting from poor adherence related to intolerable drug toxicities and complex dosing schedules.
Kristin H, Busse, Scott R, Penzak
openaire   +2 more sources

HIV Protease Inhibitors in Pregnancy

Drugs, 2013
The impact of antiretroviral therapy (ART) on the natural history of HIV-1 infection has resulted in dramatic reductions in disease-associated morbidity and mortality. Additionally, the epidemiology of HIV-1 infection worldwide is changing, as women now represent a substantial proportion of infected adults.
Nisha, Andany, Mona R, Loutfy
openaire   +2 more sources

Synthesis and pharmacological evaluation of sulfone substituted HIV protease inhibitors

Bioorganic & Medicinal Chemistry Letters, 1997
Abstract The sulfonamide substituted pyranones ( 1 ) have recently been shown to be potent HIV protease inhibitors. We prepared a series of sulfone substituted analogs and compared their biological activities to those of the corresponding sulfonamide analogs.
Theresa M. Schwartz, Gordon L. Bundy, Joseph W. Strohbach, Suvit Thaisrivongs, Paul D. Johnson, Harvey I. Skulnick, Paul K. Tomich, Janet C. Lynn, Kong Teck Chong, Roger R. Hinshaw, Thomas J. Raub, Guy E. Padbury, Lisa N. Toth   +12 more
openaire   +1 more source

Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules

Current Opinion in Infectious Diseases, 2002
Antiretroviral agents target HIV replication within infected cells. It is therefore important to focus on the pharmacology of these drugs at their site of action rather than just in plasma. Activation of nucleoside analogues to a triphosphate is essential for antiretroviral activity.
Patrick G, Hoggard, David J, Back
openaire   +2 more sources

ChemInform Abstract: Synthesis and Pharmacological Evaluation of Sulfone Substituted HIV Protease Inhibitors.

ChemInform, 1997
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
T. M. SCHWARTZ, G. L. BUNDY, J. W. STROHBACH, S. THAISRIVONGS, P. D. JOHNSON, H. I. SKULNICK, P. K. TOMICH, J. C. LYNN, K. T. CHONG, R. R. HINSHAW, T. J. RAUB, G. E. PADBURY, L. N. TOTH   +12 more
openaire   +1 more source